biomedicina slovenica

pr=Cortes : 11

  1. Kačar Mark; Cortes-Acevedo Paulina; Patel Vinesh; Carter Clive; Hughes Pamela; McGann Hugh P.; Gkrania-Klotsas Effrossyni; Baxendale Helen; Barcenas-Morales Gabriela; Doffinger Rainer; Savic Sinisa
    Neutralizing anti-interferon-[gamma] autoantibodies
    2021 ►
  2. Moysidis Stavros N.; Koulisis Nicole; Adrean Sean D.; Charles Steve; Chetty Naren; Chhablani Jay Kumar; Cisneros Cortes Javier; Embabi Sherif N.; Gordon Carmelina; Gregori Ninel Z.; Lumi Xhevat
    Autologous retinal transplantation for primary and refractory macular holes, and macular hole retinal detachments
    2021 ►
  3. Pravst Igor; Rodríguez Aguilera Juan Carlos; Cortes Rodriguez Ana Belen; Jazbar Janja; Locatelli Igor; Hristov Hristo; Žmitek Katja
    Comparative bioavailability of different coenzyme Q10 formulations in healthy elderly Individuals
    2020 ►
  4. Gennari Alessandra; Sun Z.; Hasler-Strub U.; Colleoni Marco; Moos Roger von; Cortes Jorge; Walshe J.; Ribi K.; Bernhard Jürg; Borštnar Simona
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer
    2018 ►
  5. Quintás-Cardama Alfonso; Sever Matjaž; Cortes Jorge; Kantarjian Hagop; Verstovsek Srdan
    Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis
    2013 ►
  6. Vega-Ruiz Arturo; Cortes Jorge E; Sever Matjaž; Manshouri Taghi; Quintas-Cardama Alfonso; Luthra Raja; Kantarjian Hagop M; Verstovsek Srdan
    Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
    2009 ►
  7. Nussenzveig Roberto H; Cortes Jorge; Sever Matjaž; Verstovsek Srdan
    Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
    2009 ►
  8. Sever Matjaž; Kantarjian Hagop; Pierce Sherry; Jain Nitin; Estrov Zeev; Cortes Jorge; Verstovsek Srdan
    Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
    2009 ►
  9. Pinder SE; Murray S; Ellis O; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortes-Funes H; Simoncini E; Byrne MJ; Golouh R
    The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy
    1998 ►
  10. Pestalozzi BC; Peterson HF; Gelber RD; Goldhirsch A; Gusterson BA; Trihia H; Lindtner J; Cortes-Funes H; Simmoncini E; Golouh R
    Prognostic importance of thymidylate synthase expression in early breast cancer
    1997 ►
  11. Stucchi-Goldhirsch E; Forbes J; Price KN; Castiglione M; Gelber RD; Rudenstam C-M; Lindtner J; Collins J; Cavalli F; Cortes-Funes H
    Low-dose prednisone (p) in combination with adjuvant systemic therapy (AST) for operable breast cancer (BC) is associated with increased risk of second (non-breast) malignancies.
    1994 ►

New search      Comments      Top of page Institute for Biostatistics and Medical Informatics